help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varela, L. M.
Right arrow Articles by Ip, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varela, L. M.
Right arrow Articles by Ip, M. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Endocrinology Vol. 138, No. 9 3891-3900
Copyright © 1997 by The Endocrine Society


ARTICLES

The Epidermal Growth Factor Receptor Is Not Required for Tumor Necrosis Factor-{alpha} Action in Normal Mammary Epithelial Cells1

Linda M. Varela, Kathleen M. Darcy and Margot M. Ip

Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263

Address all correspondence and requests for reprints to: Dr. Margot M. Ip, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263. E-mail: mip{at}sc3101.med.buffalo.edu


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Our laboratory has shown that tumor necrosis factor-{alpha} (TNF{alpha}) can regulate normal mammary epithelial cell (MEC) growth, morphogenesis, and, under certain circumstances, functional differentiation in a manner similar to epidermal growth factor (EGF). As TNF{alpha} has been shown to up-regulate EGF receptor (EGFR) expression and function in other systems, the present studies were undertaken to determine whether TNF{alpha} action in MEC was indirect through stimulation of the EGFR. An inhibitor of EGFR tyrosine kinase activity, PD158780, failed to block proliferation induced by 40 ng/ml TNF{alpha} and only partially inhibited growth in response to 2 ng/ml TNF{alpha}. PD158780 was also unable to suppress the extensive morphological development induced by either TNF{alpha} concentration. In contrast, the effects of TNF{alpha} and PD158780 on functional differentiation (i.e. casein accumulation) were time dependent. When measured on day 7 after 48 h of treatment, casein accumulation was unaffected by either concentration of TNF{alpha} or by PD158780. When assessed on day 21 after 16 days of treatment, however, casein levels were decreased by 40 ng/ml TNF{alpha} and increased by PD158780. Significantly, this PD158780-induced increase in casein was not observed in MEC that had been treated with both PD158780 and TNF{alpha}. These results thus suggest that EGFR tyrosine kinase activity is not necessary for TNF{alpha} action in normal MEC.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
TUMOR NECROSIS factor-{alpha} (TNF{alpha}) is a multifunctional cytokine that affects the growth, differentiation, and/or function of virtually all cell types (1, 2, 3, 4). These pleiotropic effects are mediated in part through two distinct cell surface receptors of molecular masses 55 and 75 kDa (p55 and p75, respectively), which are expressed specifically and independently of each other in varying proportions on virtually all cells (5, 6, 7). Although the receptors have some sequence homology in their extracellular domains, evidence suggests that the two actually have unique postreceptor signaling pathways and ultimately induce different responses. For example, a large majority of TNF{alpha} activities, including cytotoxicity (8, 9), antiviral activity (10), and stimulation of fibroblast proliferation (11), are mediated by p55, whereas the 75-kDa TNF receptor transduces signals for thymocyte proliferation (8), inhibition of hematopoiesis (12), and granulocyte-macrophage colony-stimulating factor secretion (13).

In contrast to the well documented cytotoxic or cytostatic effects of TNF{alpha} in breast cancer cells (2, 14, 15), our laboratory has demonstrated that TNF{alpha} actually stimulates the growth and morphological development and regulates the function of normal mammary epithelial cells (MEC) in primary culture (16). These studies used a primary culture system in which undifferentiated rat MEC, cultured in the presence of a defined, serum-free medium, proliferate, morphologically develop, and functionally differentiate to an extent comparable to that of cells within the mammary gland of a rat during lactation (17, 18, 19). Specifically, TNF{alpha} was found to stimulate MEC proliferation in both the presence and absence of epidermal growth factor (EGF), a major growth and differentiation factor for the MEC in this culture system, and we have recently determined that the p55 TNF receptor is the primary mediator of this TNF{alpha}-induced growth (20). Both TNF{alpha} and EGF also stimulated the morphological development of the MEC organoids, inducing the formation of large, well differentiated alveolar colonies that, in the case of TNF{alpha}, had extensive ductal branching (16). Lastly, TNF{alpha} modulated the functional differentiation (casein accumulation) of the MEC organoids in culture; however, these effects were more complex than its effect on either growth or morphogenesis. Higher concentrations of TNF{alpha} inhibited casein accumulation, but in the absence of EGF, lower concentrations of TNF{alpha} were found to stimulate casein accumulation at later times in culture, albeit to a lesser extent than EGF (16). In addition, we have recently determined that the two TNF receptors have opposing effects on MEC functional differentiation, with the p55 receptor signaling inhibition of casein accumulation, and p75 signaling stimulation (20).

Despite these recent discoveries, the postreceptor pathway(s) of TNF{alpha} action in normal MEC is still unknown. Indeed, it is not yet known whether the actions of TNF{alpha} are direct or indirect via the induction of another cytokine or growth factor. One potential indirect signaling pathway may involve the EGF receptor (EGFR). Previous studies have indicated that EGFRs are present on normal MEC (21, 22, 23), and that MEC can synthesize various EGFR ligands, including TGF{alpha} (24, 25), amphiregulin (26), and EGF (21, 27). In addition, numerous studies have shown that TNF{alpha} can affect the EGFR on various levels, including messenger RNA (mRNA) expression, number and binding affinity of receptors, phosphorylation status, and tyrosine kinase activity (26, 28, 29, 30, 31), and TNF{alpha} can also induce the expression of various ligands of the EGFR, including TGF{alpha} and amphiregulin (26, 29, 32). Furthermore, the two TNF receptors have been shown to have diverse effects on EGF ligand and receptor family members, with signaling via p55 mediating the up-regulation of EGFR mRNA in epithelial cells and that via p75 transducing the signal for the up-regulation of TGF{alpha} mRNA (29).

We therefore hypothesized that signals from the TNF receptors might be up-regulating EGFR expression, ligand production, and/or tyrosine kinase activity in MEC to indirectly stimulate MEC proliferation and/or differentiation. To test this latter hypothesis, we used a specific inhibitor of EGFR tyrosine kinase activity, PD158780 (compound 7f of Table 1 in 33 in an attempt to block TNF{alpha} action on normal MEC in primary culture. This compound is a potent inhibitor of the tyrosine kinase activity of members of the EGFR family, which includes the EGFR itself as well as erbB2, -B3, and -B4, but has poor inhibitory activity against the platelet-derived growth factor or fibroblast growth factor receptor tyrosine kinases (Fry, D., personal communication).


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials
Phenol red-free RPMI 1640, newborn calf serum (NCS), and gentamicin were purchased from Life Technologies (Grand Island, NY); collagenase class III was purchased from Worthington Biochemical Corp. (Freehold, NJ); dispase grade II powder (neutral protease) was a product of Boehringer Mannheim (Indianapolis, IN); and liquid dispase (50 caseinolytic units/ml) was purchased from Collaborative Biomedical Products (Bedford, MA). Phenol red-free DMEM-Ham’s F-12 (DMEM-F12; 1:1, containing 15 mM HEPES), Nonidet P-40, insulin, progesterone, hydrocortisone, ascorbic acid, apo-transferrin, fatty acid-free BSA, and 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide (MTT) were obtained from Sigma Chemical Co. (St. Louis, MO). Donkey antirabbit peroxidase-conjugated IgG was a product of Jackson ImmunoResearch Laboratories (West Grove, PA). Mouse EGF was purchased from Upstate Biotechnology (Lake Placid, NY), and ovine PRL (NIDDK oPL-20) was a gift from NIDDK, NIH (Bethesda, MD). [Methyl-3H]thymidine was purchased from DuPont-New England Nuclear (Boston, MA). Recombinant human TNF{alpha} (2.5 x 106 U/mg) was a gift from Asahi Chemical Industry Co. (Fuji, Shizuoka, Japan), and the inhibitor of EGFR tyrosine kinase activity, PD158780, was provided by Dr. David Fry at Parke-Davis (Ann Arbor, MI).

Animals
For the isolation of MEC for primary culture, virgin 50- to 55-day-old female Sprague-Dawley Crl:CD BR rats were purchased from Charles River (Wilmington, MA) and used as the source of mammary glands. Female CD2F1 mice, purchased from NCI-Frederick Cancer Research Facility, Biological Testing Branch (Frederick, MD), were used to passage the Engelbreth-Holm-Swarm (EHS) sarcoma, which was the source of the reconstituted basement membrane (RBM) matrix for the primary culture of the MEC organoids. Rats and mice were fed chow diets (Teklad, Madison, WI) ad libitum and had free access to water. Animal rooms were humidity controlled and air conditioned, with 14-h light, 10-h dark cycles (rats) or 12-h light, 12-h dark cycles (mice). The care and use of the animals was in accordance with NIH guidelines and Institute Animal Care and Use Committee regulations.

RBM matrix preparation
The RBM matrix used for the primary culture of the MEC organoids was extracted from the EHS sarcoma as previously described (17).

MEC isolation and cell culture
For the primary culture of MEC, epithelial cell organoids were isolated and cultured as previously described. Briefly, mammary glands were excised from virgin 50- to 55-day old female rats (eight per experiment), mechanically minced, suspended in 10 ml/g wet wt digestion solution [phenol red-free RPMI 1640 containing 0.2% (wt/vol) dispase II, 0.2% (wt/vol) collagenase type III, 5% (vol/vol) NCS, and 50 µg/ml gentamicin], and incubated at 37 C for approximately 13.5 h. The resultant epithelial cell organoids were pelleted by centrifugation, washed twice with DMEM-F12, and resuspended in DMEM-F12. The MEC suspension was then filtered through a 530-µm Nitex filter (Tetko, Depew, NY) to remove any large aggregates of glandular material and subsequently passed through a 60-µm Nitex filter, which trapped the MEC organoids but allowed the passage (and removal) of small cell clusters and single cells. The organoids were rinsed off the Nitex filter with DMEM-F12 (phenol red-free) containing 5% (vol/vol) NCS and 50 µg/ml gentamicin, refiltered through the 530-µm Nitex, and incubated in a plastic tissue culture flask for 4 h at 37 C; this step facilitated the attachment and removal of any remaining stromal cells from the nonadherent mammary epithelial organoids. The number of MEC within the organoids was then enumerated by counting of nuclei as previously described (17). The nonadherent MEC organoids were pelleted by centrifugation and resuspended in ice-cold RBM matrix at a concentration of 3 x 105 cells/0.2 ml matrix. Two hundred microliters of RBM matrix containing epithelial organoids was layered on top of 200 µl pregelled, cell-free RBM matrix/well of a 24-well plate. After the matrix was allowed to gel for 3 h at 37 C, 1 ml medium was added to each well. The medium was changed on day 5 as indicated below; thereafter, the medium was changed twice per week. The serum-free medium used for these studies consisted of 10 µg/ml insulin, 1 µg/ml progesterone, 1 µg/ml hydrocortisone, 5 µg/ml transferrin, 1 µg/ml PRL, 5 µM ascorbic acid, 1 mg/ml fatty acid-free BSA, and 50 µg/ml gentamicin in phenol red-free DMEM-F12. EGF (10 ng/ml; 1.6 nM) or TNF{alpha} (2 or 40 ng/ml; 0.1 or 2.3 nM, respectively) was added where noted in the text. PD158780 was dissolved in 0.1% DMSO and added to the medium immediately before use.

[3H]Thymidine incorporation assay
The MEC organoids were cultured until day 5 in the EGF- and TNF{alpha}-free medium described above. On day 5, the medium was changed, and EGF (10 ng/ml; 1.6 nM) or TNF{alpha} (2 or 40 ng/ml; 0.1 or 2.3 nM, respectively) in either the presence or absence of the EGFR tyrosine kinase inhibitor PD158780 (0.5 µM) was added, and the cultures were incubated for either 48 h (until day 7) or 16 days (until day 21) at 37 C. As a control for these studies, PD158780 alone was added to the EGF- and TNF{alpha}-free culture medium. After the cultures were pulse labeled with [3H]thymidine (5 µCi/well) for the last 4 h of incubation on either day 7 or day 21, the medium was removed, and the RBM matrix was digested away using 5 caseinolytic units/ml liquid dispase for 2 h at 37 C. The MEC organoids were washed with cold PBS, and the acid-insoluble fraction was precipitated overnight at 4 C with 1 ml 5% (wt/vol) trichloroacetic acid. The pellets were washed twice with cold 5% trichloroacetic acid, solubilized in 1 ml 0.1 N NaOH containing 0.1% (vol/vol) Triton X-100, neutralized with 100 µl 1 N HCl, and [3H]thymidine incorporation was determined by liquid scintillation counting.

Quantitation of cell number (MTT assay)
Culture conditions and treatment were the same as those described above for the [3H]thymidine incorporation assay. Cell number was quantitated on days 7 and 21 using the MTT assay that we have previously described (16). In this assay, viable cells convert the soluble tetrazolium MTT dye into insoluble blue formazan crystals, whereas nonviable cells are unable to metabolize the MTT substrate and, thus, are not counted. The total viable cell number is then determined by extrapolation of the absorbance intensity from a standard curve that is constructed for each experiment. In brief, 200 µl MTT (5 mg/ml in PBS) were added per ml medium, and cultures were incubated for 16 h at 37 C. After removal of the medium and rinsing of each well with PBS, the RBM matrix was digested by adding 1 ml dispase (5 caseinolytic units/ml)/well and incubating for 2 h at 37 C. The digested material was transferred to glass tubes, and each well was rinsed with 1 ml PBS. The cells were then separated from the digested matrix by centrifugation, and the pellet was dissolved in isopropanol and recentrifuged. Absorbance at 570 nm was read in a Bio-Tek model EL311 plate reader (Winooski, VT). Standard curves using the newly isolated MEC were set up for each experiment. It was also established that PD158780 did not interfere with the MTT assay, as nuclei counts on day 21 did not differ significantly from cell counts obtained using the MTT assay (data not shown).

Morphological analysis
Culture conditions and treatment were as described above for the [3H]thymidine incorporation assay. The morphological appearance of the MEC organoids was assessed and quantitated on days 7 and 21 of culture (during the last 4–6 h of treatment) by light microscopic observation. Colonies were classified into four main groups: end bud-like, alveolar, squamous, and atypical hybrid (19). The end bud-like colonies are pale rust in color, have a more simplistic lobular structure with fewer, smaller ductal projections, and are primarily composed of immature epithelial cells that show little or no evidence of functional differentiation. In contrast, the dark brown or black alveolar colonies are larger, have a more complex, multilobular structure with extensive ductal projections, and are composed of morphologically and functionally differentiated MEC organized into a classical alveolar arrangement. Squamous colonies contain concentrically compacted acellular material in a keratotic whorl pattern (16, 34), and atypical hybrid colonies are defined as hybrids of alveolar and squamous colonies. Photographs of the organoids were taken with a Nikon FX-35A camera mounted on an Olympus CK2 inverted microscope (Melville, NY).

Assessment of functional differentiation (measurement of casein accumulation)
Culture conditions and treatment were as described above, and samples were harvested on days 7 and 21 of culture as previously described (16). Casein levels were assayed in three wells per treatment group using the standard casein enzyme-linked immunosorbent assay (ELISA) previously developed by our laboratory (18). In addition, casein accumulation by MEC was determined using a modification of a recently described Western blot procedure (20). In this case, samples were mixtures of the triplicate wells for each treatment group. The samples were normalized for loading on the basis of either equivalent protein contents (after Bio-Rad protein analysis) or equivalent cell number. In either case, extracts of MEC plus RBM matrix were diluted with 4-fold concentrated Laemmli sample buffer (35), boiled for 4 min, subjected to electrophoresis on a 12.5% polyacrylamide-SDS gel according to the method of Laemmli (35), and transferred to nitrocellulose. After the membranes were blocked overnight at 4 C with 5% (wt/vol) Blotto (nonfat dried milk) in TBS buffer (150 mM NaCl and 10 mM Tris, pH 7.4, at 25 C), they were rinsed in TBS containing 0.5% (wt/vol) BSA (TBS/BSA) and incubated for 2 h at room temperature with a rabbit polyclonal antibody against the rat casein proteins (18) (1:3000 dilution) in TBS/BSA. Blots were then washed in TBS/BSA, incubated with peroxidase-conjugated donkey antirabbit antiserum (1:5000 dilution in TBS/BSA) for 60 min at room temperature, washed in TBS/BSA containing 0.01% (vol/vol) Tween-20, and developed using the enhanced chemiluminescence system (Amersham).

Statistics
Statistical significance was determined using a one-way ANOVA with the Student-Newman-Keuls test for pairwise multiple comparisons. P < 0.05 was judged to be statistically significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Effect of PD158780 on the TNF{alpha}-induced proliferation of normal MEC
Preliminary studies that evaluated the effects of various concentrations of the EGFR tyrosine kinase inhibitor on MEC indicated that at 0.5 µM, PD158780 was inhibitory to EGF-induced effects, but was not cytotoxic to the cells (Darcy, K. M., unpublished observation). Thus, this concentration of PD158780 was used in an attempt to inhibit the effects of TNF{alpha} on normal MEC growth and differentiation.

First, the ability of PD158780 to block TNF{alpha}-induced DNA synthesis in normal MEC was investigated using a [3H]thymidine incorporation assay. When assessed on day 7 of culture after 48 h of treatment, the EGFR tyrosine kinase inhibitor only modestly suppressed the increase in [3H]thymidine incorporation stimulated by 40 ng/ml TNF{alpha} (Fig. 1Go, bars 5 and 6), but reduced DNA synthesis in response to 2 ng/ml TNF{alpha} by approximately 50% (Fig. 1Go, bars 7 and 8). In contrast, the EGF-induced increase in DNA synthesis was completely blocked by PD158780 (Fig. 1Go, bars 3 and 4). Moreover, the EGFR tyrosine kinase inhibitor alone was found to cause 50% inhibition of [3H]thymidine incorporation. As no EGF was present in the culture medium, we believe that this latter inhibition was due to the blockage of the activity of endogenous EGFR ligands either produced by the MEC themselves or present in the RBM matrix.



View larger version (48K):
[in this window]
[in a new window]
 
Figure 1. The effects of EGF, TNF{alpha}, and PD158780 on thymidine incorporation by MEC on day 7 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 48 h from days 5–7 of culture. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780 (P < 0.05). Each bar represents the mean ± SEM of triplicate culture wells. This graph is representative of four independent experiments. The slight inhibitory effect of PD158780 on thymidine incorporation in response to 40 ng/ml TNF{alpha} in this experiment was statistically insignificant in three other experiments.

 
The MEC culture system used herein also permits both morphological and functional differentiation over a 3-week period. To determine whether the pathway of TNF{alpha} action changed as the MEC differentiated, the cells were also treated until the end of the 21-day culture period (for a total of 16 days). When measured on day 21, [3H]thymidine incorporation by MEC treated with either concentration of TNF{alpha} was not increased relative to the control value as it had been on day 7 (Figs. 1Go and 2Go, compare bars 5 and 7 to bar 1). However, it can be seen that PD158780 still had no effect on DNA synthesis in the presence of 40 ng/ml TNF{alpha} (Fig. 2Go, compare bars 6 and 5), but again caused a 50% inhibition at the lower, 2 ng/ml concentration (Fig. 2Go, compare bar 8 with bar 7). Of considerable interest was the marked difference in thymidine incorporation between TNF{alpha}- and EGF-treated MEC at this time. In contrast to both TNF{alpha}-treated groups and to day 7, thymidine incorporation by MEC grown in the presence of EGF for 16 days was dramatically decreased compared with the control group; moreover, PD158780 had no further inhibitory effect on DNA synthesis in the presence of EGF. Also noteworthy was the marked inhibitory effect of PD158780 on thymidine incorporation in the absence of added growth factor (Fig. 2Go, compare bars 2 and 1).



View larger version (40K):
[in this window]
[in a new window]
 
Figure 2. The effects of EGF, TNF{alpha}, and PD158780 on thymidine incorporation by MEC when measured on day 21 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 16 days from days 5–21 of culture. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780 (P < 0.05). #, Significantly different from the EGF-treated group (P < 0.05). Each bar represents the mean ± SEM of triplicate culture wells. This graph is representative of two independent experiments.

 
Concurrently, the total viable cell number was also quantitated in the various treatment groups to determine the balance between cell growth and death in response to TNF{alpha} and to determine whether this balance was affected by inhibition of EGFR tyrosine kinase activity. In contrast to the stimulatory effect on thymidine incorporation, neither concentration of TNF{alpha}, in either the presence or absence of PD158780, had any effect on viable cell number after 48 h (day 7). Cell number was increased in the EGF-treated group, however, and this increase was completely suppressed by PD158780, whereas cell number was unaffected by the 48-h treatment with PD158780 alone (Fig. 3Go).



View larger version (44K):
[in this window]
[in a new window]
 
Figure 3. The effects of EGF, TNF{alpha}, and PD158780 on viable cell number when measured on day 7 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 48 h from days 5–7 of culture. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780 (P < 0.05). Each bar represents the mean ± SEM of triplicate culture wells. This graph is representative of three independent experiments.

 
When assessed on day 21 after 16 days of treatment, the viable cell number in both TNF{alpha}-treated groups was increased compared with that on day 7 and was significantly higher than the cell number in the EGF-treated culture (Fig. 4Go, compare bars 5 and 7 to bar 3). More significantly, PD158780 was unable to block the increase in viable cell number induced by 40 ng/ml TNF{alpha} (Fig. 4Go, compare bars 5 and 6), but partially suppressed the increase in cell number in response to 2 ng/ml TNF{alpha}. Finally, the EGF-induced increase in viable cell number was blocked by PD158780 (Fig. 4Go) as it had been on day 7, whereas the EGFR tyrosine kinase inhibitor alone had no effect (compare bars 1 and 2). Thus, when taken together, these data suggest that EGFR tyrosine kinase activity is not required for TNF{alpha} to induce the proliferation of normal MEC in culture, although the pathway(s) activated by both the TNF{alpha} and EGF receptors may actin concert to stimulate MEC growth under certain circumstances.



View larger version (54K):
[in this window]
[in a new window]
 
Figure 4. The effects of EGF, TNF{alpha}, and PD158780 on viable cell number when measured on day 21 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 16 days from days 5–21 of culture. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780 (P < 0.05). #, Significantly different from the EGF-treated group (P < 0.05). Each bar represents the mean ± SEM of triplicate culture wells. This graph is representative of three independent experiments.

 
Effect of PD158780 on TNF{alpha}-induced morphological differentiation
We have previously shown that both TNF{alpha} and EGF can stimulate the ductal and alveolar morphogenesis of MEC in culture while suppressing the outgrowth of colonies with an atypical or squamous epithelial morphology (16, 34). To determine whether the EGFR was involved in the pathway by which TNF{alpha} stimulated the morphological development of the MEC, the ability of PD158780 to inhibit TNF{alpha}-induced morphogenesis was assessed. Morphological changes after 48 h of treatment were subtle (data not shown). In both TNF{alpha}- and EGF-treated groups, the percentage of the less differentiated, end bud-like colonies was slightly decreased, whereas the percentage of the more differentiated, alveolar colonies was increased; the percentage of squamous and atypical hybrid colonies in all groups was negligible at this time. The EGFR tyrosine kinase inhibitor had no significant effect on colony morphology in either the presence or absence of TNF{alpha} or EGF.

In contrast, TNF{alpha} induced significant changes in both colony type and size after 16 days of treatment. Specifically, 40 ng/ml TNF{alpha} stimulated the formation of complex, lobulo-alveolar colonies that were significantly larger than those induced by EGF (Fig. 5Go, compare j with f and g) and which were interconnected by extensive ductal branching (Figs. 5jGo and 6Go). Furthermore, TNF{alpha} also inhibited the development of both squamous and atypical colonies (Fig. 6Go). More importantly, the EGFR tyrosine kinase inhibitor was unable to inhibit this expansive TNF{alpha}-induced morphogenesis, as colonies that developed in the presence of TNF{alpha} plus PD158780 were as large, viable, and morphologically developed as those that developed in the presence of TNF{alpha} alone (Fig. 5Go, j and k, and Fig. 6Go). The 2 ng/ml concentration of TNF{alpha} also stimulated alveolar and ductal morphogenesis, although the effects were less pronounced than those of 40 ng/ml TNF{alpha}, and PD158780 was still unable to block this TNF{alpha}-induced morphological differentiation (16) (data not shown).



View larger version (96K):
[in this window]
[in a new window]
 
Figure 5. The effects of EGF, TNF{alpha}, and PD158780 on the morphological appearance of MEC organoids in primary culture after 16 days of treatment. Control: a, squamous epithelial organoids; b, atypical organoid (hybrid of multilobular alveolar and squamous colonies); c, multilobular alveolar organoid. + PD158: d and e, multilobular alveolar organoids; note the disrupted appearance. + EGF: f and g, multilobular alveolar organoids. + EGF and PD158: h and i, multilobular alveolar organoids; note disrupted appearance. + TNF{alpha} (40 ng/ml): j, ductal-alveolar colony network. + TNF{alpha} (40 ng) and PD158: k, ductal-alveolar colony network; note the lack of effect of PD158 in the presence of TNF{alpha}. Magnification in all photographs is the same; bars = 100 µm.

 


View larger version (33K):
[in this window]
[in a new window]
 
Figure 6. The effects of EGF, TNF{alpha}, and PD158780 on the morphological differentiation of MEC organoids in primary culture. The morphological type of each colony was classified and quantitated on day 21 of culture. Four main colony types were quantitated, end bud-like, alveolar, squamous, and atypical hybrid, and the proportion of each is expressed as a percentage of total epithelial colonies. Bars represent the mean ± SEM of triplicate culture wells. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780 (P < 0.05). This graph is representative of three independent experiments.

 
In contrast to its inability to alter morphological development in the presence of TNF{alpha}, the EGFR tyrosine kinase inhibitor had several noteworthy effects on MEC morphogenesis when added alone or in combination with EGF. Unexpectedly, PD158780 alone mimicked the ability of EGF to both suppress squamous and atypical colony formation and to stimulate the formation of the more differentiated, lobular-alveolar colonies (Fig. 6Go). These latter colonies, however, tended to be quite small compared to TNF{alpha}- or EGF-treated colonies (Fig. 5dGo), and any larger alveolar colonies that developed in the presence of PD158780 alone appeared to be highly disrupted and were surrounded by small cellular bodies that had apparently broken off of the periphery of the alveolar organoids (Fig. 5eGo). Furthermore, organoids treated with both EGF and PD158780 were not as large as colonies treated with EGF alone (Fig. 5Go, compare h and i to g), and many of the alveolar colonies in this group also appeared to be highly disrupted (Fig. 5iGo).

Effect of PD158780 on TNF{alpha}-modulated MEC functional differentiation
Previous studies by our laboratory determined that TNF{alpha} had a complex, biphasic effect on casein production by MEC; a higher concentration of TNF{alpha} (40 ng/ml) inhibited functional differentiation, whereas in the absence of EGF, a lower concentration of TNF{alpha} (2 ng/ml) enhanced casein accumulation (16). To determine whether these effects of TNF{alpha} might be mediated through the EGFR, the ability of PD158780 to interfere with the effects of TNF{alpha} on casein accumulation by MEC was measured using both Western blot analysis and an ELISA (18). When examined on day 7, casein accumulation was unaffected by the 48-h treatment with either 2 or 40 ng/ml TNF{alpha} (Fig. 7Go, lane 5, and data not shown), and casein levels were also unchanged in MEC that had been treated with both TNF{alpha} and PD158780 (Fig. 7Go, lane 6, and data not shown). The EGFR tyrosine kinase inhibitor completely blocked the increased accumulation of all casein isoforms in response to EGF (Fig. 7Go, compare lanes 3 and 4), whereas PD158780 alone had no significant effect on casein levels (Fig. 7Go, compare lanes 2 and 1). Casein levels in all but the EGF-treated group were below the limits of detectability by ELISA (data not shown).



View larger version (61K):
[in this window]
[in a new window]
 
Figure 7. The effects of EGF, TNF{alpha}, and PD158780 on casein protein accumulation by MEC when measured on day 7 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 48 h from days 5–7. Equivalent amounts of protein (10 µg) from extracts of MEC plus RBM matrix were loaded into each lane and subjected to Western blot analysis for casein. Each lane represents a combination of triplicate wells for each group. This blot is representative of three independent experiments. A second Western blot, in which loading was based on an equivalent number of cells in each lane, was virtually identical (data not shown).

 
When measured on day 21, however, casein levels were significantly decreased by the 16-day treatment with 40 ng/ml TNF{alpha}, and the EGFR tyrosine kinase inhibitor had no effect on this TNF{alpha}-induced inhibition (Fig. 8AGo, compare lanes 1, 5, and 6, and Fig. 8BGo). Despite its ability to significantly stimulate both MEC growth and morphogenesis, 2 ng/ml TNF{alpha} had no effect on casein levels after 16 days of treatment, even though this TNF{alpha} concentration had previously been shown to increase casein accumulation by MEC at later times in culture (Fig. 8AGo, lanes 1 and 7, and Fig. 8BGo). Casein levels were also unchanged in MEC that had been treated with both 2 ng/ml TNF{alpha} and PD158780.



View larger version (30K):
[in this window]
[in a new window]
 
Figure 8. The effects of EGF, TNF{alpha}, and PD158780 on casein accumulation by MEC when measured on day 21 of culture. MEC were cultured in serum-free medium lacking EGF, TNF{alpha}, and drug (control) until day 5; the medium was then changed, and the MEC were treated as indicated for 16 days from days 5–21 of culture. A, Western blot analysis of casein protein accumulation in extracts of MEC plus RBM matrix. Loading was based on an equivalent number of cells (5 x 103) per lane, and each lane represents a combination of triplicate wells for each group. This blot is representative of three independent experiments. B, Determination of casein accumulation by ELISA. Casein levels in extracts of MEC plus RBM matrix were analyzed by ELISA, and results are expressed as nanograms per 105 cells. Bars represent the mean ± SEM of triplicate wells. *, Significantly different from the control (P < 0.05). +, Significantly different from the corresponding group without PD158780. The absolute micrograms of casein per well (uncorrected for cell number) were as follows: 9.44 ± 2.08 (control), 8.85 ± 1.04 (+ PD158), 19.6 ± 8.37 (+ EGF), 16.5 ± 1.26 (+ EGF and PD158), 3.61 ± 1.43 (+ 40 ng/ml TNF{alpha}), 2.45 ± 0.85 (+ 40 ng TNF{alpha} and PD158), 12.3 ± 1.64 (+ 2 ng/ml TNF{alpha}), and 5.81 ± 0.79 (+ 2 ng TNF{alpha} and PD158). This graph is representative of three experiments.

 
Unexpectedly, casein accumulation was increased in MEC that had been treated for 16 days with PD158780 alone or with both EGF and PD158780 (Fig. 8Go, A and B). This latter effect was in direct contrast to the inhibitory effect of PD158780 on EGF-induced casein accumulation after 48 h. Lastly, it should also be noted that this PD158780-induced increase in casein accumulation was not observed in the presence of either concentration of TNF{alpha} (Fig. 8Go, A and B).


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
EGFR tyrosine kinase activity is not necessary for TNF{alpha}-induced MEC proliferation
The results of our previous studies indicated that the combined mitogenic actions of TNF{alpha} and EGF on normal MEC were less than additive (16). This suggested that TNF{alpha} and EGF might be activating a common growth stimulatory pathway, and that the mitogenic effect of TNF{alpha} might be mediated, at least in part, via activation of the EGFR in response to signals from the p55 TNF receptor. On the other hand, this earlier data also suggested that the mitogenic signaling pathway triggered by the p55 TNF receptor may have an EGFR-independent component, as TNF{alpha} was shown to increase total cell number to a higher level than that observed with optimal levels of EGF (16, 17, 34). The studies presented herein suggest that EGFR tyrosine kinase activity is not required for TNF{alpha} to stimulate MEC proliferation. PD158780 was unable to inhibit proliferation in response to 40 ng/ml TNF{alpha} and only partially suppressed the growth-promoting effects of 2 ng/ml TNF{alpha}. Although we cannot rule out the possibility that PD158780 may be inhibiting an, as yet undiscovered, tyrosine kinase that is activated by 2 ng/ml TNF{alpha}, this latter observation suggests that signaling pathway(s) activated by endogenous EGFR ligands may act in concert with pathways activated by the lower concentration of TNF{alpha} to stimulate growth. In support of this theory, EGF and TNF{alpha} have been shown to preferentially activate different members of the mitogen-activated protein kinase family in other cell types. EGF strongly stimulates ERK1 and ERK2 activity, whereas TNF{alpha} induces a more pronounced activation of the c-Jun N-terminal kinases (JNKs) (36, 37, 38). Thus, when EGFR activation is blocked by PD158780, such that ERK1 and/or ERK2 may no longer be activated by this receptor, growth in the presence of 2 ng/ml TNF{alpha} may be partially, but not completely, suppressed.

In contrast, the higher (40 ng/ml) concentration of TNF{alpha} may be able to directly activate ERK1 and/or ERK2, such that the blockage of endogenous EGFR ligand-induced action by PD158780 has no effect on DNA synthesis in response to this TNF{alpha} concentration. Even though TNF{alpha} is not as powerful a stimulus for ERK1 and ERK2 as EGF, numerous studies have demonstrated that TNF{alpha} can activate these enzymes (39, 40, 41, 42), so it could be proposed that the higher concentration of TNF{alpha} may activate both the JNK and ERK enzymatic signaling cascades to stimulate MEC growth. Furthermore, a study by Sluss et al. (43) has demonstrated that there are two JNK protein kinase isoforms, JNK1 and JNK2, and that the activation of these protein kinases by TNF{alpha} is concentration dependent. Therefore, it could be postulated that 40 ng/ml TNF{alpha} activates both JNK1 and JNK2, whereas the lower TNF{alpha} concentration only triggers the activation of one JNK isoform. The higher TNF{alpha} concentration may also preferentially activate JNK2, which has been shown to be more potent in inducing the phosphorylation of c-jun than JNK1 (43). The specific roles of both of the ERK and JNK mitogen-activated protein kinase isoforms in stimulating MEC growth in response to both TNF{alpha} and EGF are currently under investigation.

The differential effects of TNF{alpha} and EGF on MEC proliferation
The distinct effects of TNF{alpha} and EGF on MEC proliferation after different times in culture were intriguing. When assessed on day 7, thymidine incorporation, but not cell number, was increased in response to TNF{alpha}, whereas both DNA synthesis and cell number were increased by EGF. This observation further supports our contention that the pathways of TNF{alpha}- and EGF-induced growth in normal MEC are different. In addition, this difference in cell number between the TNF{alpha}- and EGF-treated groups may be due to the ability of TNF{alpha} to increase the overall rate of cell turnover at this time. As several studies have demonstrated that TNF{alpha} can be either cytotoxic or mitogenic to certain cell types (44, 45), it is possible that in addition to an overall stimulation of MEC proliferation, TNF{alpha} may be cytotoxic to a specific subset of MEC within the cultures, such that there is no initial net increase in cell number. However, once the MEC to which TNF{alpha} is cytotoxic have been eliminated, the proliferative effects of TNF{alpha} may become apparent. EGF, in contrast, may have no effect on the rate of cell turnover at this time; thus, its growth stimulatory effects are immediately evident.

In contrast to day 7, the total cell number on day 21 in the groups treated with either 2 or 40 ng/ml TNF{alpha} was significantly higher than that in the EGF-treated cultures. Of further interest, however, was the observation that MEC cultured in the presence of either concentration of TNF{alpha} were still actively synthesizing DNA at this time, albeit at a reduced level compared with that on day 7, whereas DNA synthesis by EGF-treated MEC was significantly lower than the level in TNF{alpha}-treated cells. The level of [3H]thymidine incorporation by the EGF-treated cells on day 21 was also significantly lower than the level on day 7 and was actually 3.5-fold lower than thymidine incorporation by MEC cultured in the absence of EGF or TNF{alpha}. This latter observation suggests that EGF may be acting to inhibit cell growth at this time; however, the fact that PD158780 did not reverse this inhibition argues against this supposition. Rather, the data suggest a loss of responsiveness of the EGF-treated cells to EGF, perhaps by down-regulation of EGFR activity in response to the 16-day EGF treatment. Alternatively, or perhaps in addition, several groups have reported that EGFR levels decrease during pregnancy and lactation (22, 23) (Darcy, K. M., manuscript in preparation), and we have recently determined that EGFR levels decline in conjunction with the morphological and functional differentiation of MEC in primary culture (Darcy, K. M., manuscript in preparation).

In any case, the different effects of TNF{alpha} and EGF on DNA synthesis and cell number at different times in culture strongly suggest that the mitogenic actions of TNF{alpha} and EGF are mediated through independent pathways, even though there may be cooperativity between these pathways under some circumstances. TNF{alpha} may also be acting on a cell population that is unresponsive to EGF. For example, both TNF{alpha} and EGF may be able to regulate the growth and differentiation of immature MEC, whereas TNF{alpha} may also be able to stimulate the proliferation of a putative stem cell population and/or effect the death of a small subset of cells early in culture.

The EGFR tyrosine kinase inhibitor did not block TNF{alpha}-induced morphological development of normal MEC
The extensive branching alveolar morphogenesis that was stimulated by both concentrations of TNF{alpha} was completely unaffected by PD158780, suggesting that the pathway of TNF{alpha}-induced morphological development is not dependent on EGFR tyrosine kinase activity. This conclusion is further supported by the observation that TNF{alpha} actually induced the formation of larger colonies with more expansive ductal branching than EGF. This difference between TNF{alpha}- and EGF-stimulated morphogenesis may be due to the differential ability of TNF{alpha} and EGF to modulate the production and/or activity of matrix metalloproteinases (MMPs), which could then affect the remodeling of the ECM. Previous studies in our laboratory have shown that MMP-9 (the 92-kDa type IV collagenase) activity in conditioned medium from MEC was increased by TNF{alpha}, but decreased by EGF (46, and our unpublished observations). Therefore, the TNF{alpha}-induced remodeling of the ECM may permit the pronounced ductal branching and alveolar morphogenesis that occurs in response to this cytokine, whereas the inability of EGF to increase MMP-9 activity may explain why EGF does not stimulate branching morphogenesis to the same extent as TNF{alpha}.

In addition, it should be noted that PD158780 alone had several interesting morphological effects. Earlier studies in our laboratory have shown that in the absence of EGF, branching alveolar morphogenesis was decreased, and the formation of both atypical hybrid and squamous colonies was enhanced (16, 34). In the current studies, however, treatment of the MEC with an inhibitor of EGFR tyrosine kinase activity actually permitted alveolar morphogenesis, although the PD158780-treated colonies were smaller than those treated with either EGF or TNF{alpha}. As PD158780 was not present for the first 5 days of culture, endogenous EGFR ligands produced by the MEC or within the RBM may have initiated the process of morphological differentiation such that the subsequent inhibition of EGFR tyrosine kinase activity was unable to inhibit morphogenesis once it had begun. This hypothesis concurs with previous studies in our laboratory in which alveolar morphogenesis proceeded even when EGF was removed from the culture medium after the first few days of culture (34). However, PD158780 also induced the apparent disintegration of the alveolar colonies when added alone or in combination with EGF (but not in the presence of TNF{alpha}), so even though PD158780 did not inhibit alveolar morphogenesis, inhibition of the EGFR tyrosine kinase activity resulted in the apoptotic death of the lobulo-alveolar organoids (47). When taken together with the aforementioned data on the effects of EGF on DNA synthesis at different times as well as with earlier studies by both our laboratory (34) and the Hynes group (48), it thus appears that EGF is needed at early times in culture (e.g. day 7) for proliferation as well as for rendering MEC competent to respond to lactogenic hormones. After differentiation, however, EGF may become a survival factor that serves to prevent apoptosis and maintain the existing state of the gland rather than stimulate further growth and/or development.

The EGFR tyrosine kinase inhibitor did not block the effects of TNF{alpha} on MEC functional differentiation
In accordance with our previous studies, casein accumulation by MEC was inhibited by a 16-day treatment with 40 ng/ml TNF{alpha}. As PD158780 was unable to alter this effect, it appears that the EGFR is not involved in the pathway by which 40 ng/ml TNF{alpha} regulates casein accumulation. In contrast to our previous studies, casein accumulation was not increased after long term treatment with 2 ng/ml TNF{alpha}. This apparent discrepancy may be due to the fact that TNF{alpha} was not added until day 5 in the current study, whereas TNF{alpha} had been present from days 0–21 of culture in the former studies. In addition, the stimulatory effect of 2 ng/ml TNF{alpha} on casein may have been masked because casein levels in the control group were unusually high in this series of experiments; this phenomenon may be due to the activity of endogenous EGFR ligands either produced by the MEC themselves or present in the RBM matrix.

Surprisingly, casein accumulation was increased in MEC that had been treated for 16 days with PD158780 alone or in combination with EGF. As studies by our laboratory have shown that casein accumulation by MEC is significantly decreased in the absence of EGF, this observation was somewhat unexpected. It could be argued that this PD158780-induced increase in casein may be due in part to the 2-fold increase in the percentage of the alveolar casein-producing colonies in this group; however, several factors argue against this explanation. First, in both EGF- and EGF- plus PD158780-treated cultures, the percentage of alveolar colonies was increased to the same extent compared with the control group, yet casein levels were higher in MEC treated with both EGF and PD158780 than in MEC treated with EGF alone. In addition, TNF{alpha} increased the percentage of alveolar colonies, but casein accumulation by TNF{alpha}-treated MEC was either decreased or unaffected depending on the TNF{alpha} concentration. Therefore, the increased percentage of alveolar colonies cannot completely account for the increase in casein levels in the PD158780-treated cultures.

In summary, the studies presented herein suggest that the modulation of MEC growth and development by TNF{alpha} does not require EGFR tyrosine kinase activity. Specifically, EGFR tyrosine kinase activity is not necessary for TNF{alpha} to stimulate the proliferation of normal MEC in culture; however, low concentrations of TNF{alpha} may act in concert with EGF to stimulate MEC growth. In addition, the EGFR tyrosine kinase inhibitor had no effect on the ability of TNF{alpha} to either stimulate MEC morphogenesis or to regulate casein accumulation by MEC. Finally, the data suggest that the function of the EGFR changes during MEC development in vitro, possibly as the result of a decrease in EGFR expression. Further analysis of both the pathway of TNF{alpha} action and the role of EGF are currently underway to determine their respective contributions to the regulation of mammary gland development.


    Acknowledgments
 
The authors thank Sue M. Shoemaker for her excellent technical expertise in performing the casein ELISA, Dr. David Fry at Parke-Davis for providing the EGF receptor tyrosine kinase inhibitor PD158780, and Asahi Chemical Industry Co. for supplying TNF{alpha}. We are also indebted to Ms. W. Shea, M. Jane Ehrke, and Drs. Molly Kulesz-Martin and Daniel Medina for helpful discussions.


    Footnotes
 
1 This work was supported by NIH Grant CA-57317 (to M.M.I.), DOD Predoctoral Grant DAMD17–94-J-4158 (to L.M.V.), NIH Training Grant CA-09072, and NIH Core Grant CA-16056. Back

Received April 3, 1997.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H 1986 Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83:5233–5237[Abstract/Free Full Text]
  2. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA 1985 Recombinant human tumor necrosis factor-{alpha}: effects on proliferation of normal and transformed cells in vitro. Science 230:943–945[Abstract/Free Full Text]
  3. Camussi G, Albano E, Tetta C, Bussolino F 1991 The molecular action of tumor necrosis factor-{alpha}. Eur J Biochem 202:3–14[Medline]
  4. Tracey KJ 1994 Tumour necrosis factor-alpha. In: Thomson A (ed) The Cytokine Handbook. Academic Press, San Diego, vol 2:289–304
  5. Hohmann H-P, Remy R, Brockhaus M, van Loon APGM 1989 Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 264:14927–14934[Abstract/Free Full Text]
  6. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H 1990 Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87:3127–3131[Abstract/Free Full Text]
  7. Tartaglia LA, Goeddel DV 1992 Two TNF receptors. Immunol Today 13:151–153[CrossRef][Medline]
  8. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Goeddel DV 1991 The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88:9292–9296[Abstract/Free Full Text]
  9. Tartaglia LA, Rothe M, Hu Y-F, Goeddel DV 1993 Tumor necrosis factor’s cytotoxic activity is signaled by the p55 TNF receptor. Cell 73:213–216[CrossRef][Medline]
  10. Wong GHW, Tartaglia LA, Lee MS, Goeddel DV 1992 Antiviral activity of tumor necrosis factor (TNF) is signaled through the 55-kDa receptor, type I TNF. J Immunol 149:3350–3353[Abstract]
  11. Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M 1986 Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163:632–643[Abstract/Free Full Text]
  12. Jacobsen FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slordal L, Jacobsen SEW 1994 Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis. Proc Natl Acad Sci USA 91:10695–10699[Abstract/Free Full Text]
  13. Vandenabeele P, Declercq W, Vercammen D, Van de Craen M, Grooten J, Loetscher H, Brockhaus M, Lesslauer W, Fiers W 1992 Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med 176:1015–1024[Abstract/Free Full Text]
  14. Dollbaum C, Creasey AA, Dairkee SH, Hiller AJ, Rudolph AR, Lin L, Vitt C, Smith HS 1988 Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin. Proc Natl Acad Sci USA 85:4740–4744[Abstract/Free Full Text]
  15. Pusztai L, Lewis CE, McGee JO 1993 Growth arrest of the breast cancer cell line, T47D, by TNF{alpha}; cell cycle specificity and signal transduction. Br J Cancer 67:290–296[Medline]
  16. Ip MM, Shoemaker SF, Darcy KM 1992 Regulation of rat mammary epithelial cell proliferation and differentiation by tumor necrosis factor {alpha}. Endocrinology 130:2833–2844[Abstract/Free Full Text]
  17. Hahm HA, Ip MM 1990 Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. I. Regulation of proliferation by hormones and growth factors. In Vitro Cell Dev Biol 26:791–802[Medline]
  18. Hahm HA, Ip MM, Darcy K, Black JD, Shea WK, Forczek S, Yoshimura M, Oka T 1990 Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. II. Functional differentiation under serum-free conditions. In Vitro Cell Dev Biol 26:803–814[Medline]
  19. Darcy KM, Black JD, Hahm HA, Ip MM 1991 Mammary organoids from immature virgin rats undergo ductal and alveolar morphogenesis when grown within a reconstituted basement membrane. Exp Cell Res 196:49–65[CrossRef][Medline]
  20. Varela LM, Ip MM 1996 Tumor necrosis factor-{alpha}: a multifunctional regulator of mammary gland development. Endocrinology 137:4915–4924[Abstract]
  21. Bates SE, Valverius EM, Ennis BW, Bronzert DA, Sheridan JP, Stampfer MR, Mendelsohn J, Lippman ME, Dickson RB 1990 Expression of the transforming growth factor-{alpha}/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126:596–607[Abstract/Free Full Text]
  22. Edery M, Pang K, Larson L, Colosi T, Nandi S 1985 Epidermal growth factor receptor levels in mouse mammary glands in various physiological states. Endocrinology 117:405–411[Abstract/Free Full Text]
  23. Moorby CD, Taylor JA, Forsyth IA 1995 Transforming growth factor-{alpha}: receptor binding and action on DNA synthesis in the sheep mammary gland. J Endocrinol 144:165–171[Abstract/Free Full Text]
  24. McAndrew J, Rudland PS, Platt-Higgins AM, Smith JA 1994 Immunolocalization of alpha-transforming growth factor in the developing rat mammary gland in vivo, rat mammary cells in vitro and in human breast disease. Histochem J 26:355–366[CrossRef][Medline]
  25. McAndrew J, Fernig DG, Rudland PS, Smith JA 1994 Secretion of transforming growth factor alpha and expression of its receptor in human mammary cell lines. Growth Factors 10:281–287[Medline]
  26. Schmiegel W, Roeder C, Schmielau J, Rodeck U, Kalthoff H 1993 Tumor necrosis factor {alpha} induces the expression of transforming growth factor {alpha} and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci USA 90:863–867[Abstract/Free Full Text]
  27. Snedeker SM, Brown CF, DiAugustine RP 1991 Expression and functional properties of transforming growth factor {alpha} and epidermal growth factor during mouse mammary gland ductal morphogenesis. Proc Natl Acad Sci USA 88:276–280[Abstract/Free Full Text]
  28. Donato NJ, Gallick GE, Steck PA, Rosenblum MG 1989 Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem 264:20474–20481[Abstract/Free Full Text]
  29. Kalthoff H, Roeder C, Brockhaus M, Thiele H, Schmiegel W 1993 Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor {alpha} and epidermal growth factor receptor mRNA. J Biol Chem 268:2762–2766[Abstract/Free Full Text]
  30. Novotny-Smith CL, Zorbas MA, Mcisaac AM, Irimura T, Boman BM, Yeoman LC, Gallick GE 1993 Down-modulation of epidermal growth factor receptor accompanies TNF-induced differentiation of the DiFi human adenocarcinoma cell line toward a goblet-like phenotype. J Cell Physiol 157:253–262[CrossRef][Medline]
  31. Perez M, Donato NJ 1996 Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity. J Interferon Cytokine Res 16:307–314[Medline]
  32. Woodworth CD, McMullin E, Iglesias M, Plowman GD 1995 Interleukin 1{alpha} and tumor necrosis factor {alpha} stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci USA 92:2840–2844[Abstract/Free Full Text]
  33. Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou HR, Fry DW, McMichael A, Denny WA 1996 Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP-binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem 39:1823–1835[CrossRef][Medline]
  34. Darcy KM, Shoemaker SF, Lee P-PH, Vaughan MM, Black JD, Ip MM 1995 Prolactin and epidermal growth factor regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J Cell Physiol 163:346–364[CrossRef][Medline]
  35. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685[CrossRef][Medline]
  36. Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA 1994 Tumor necrosis factor {alpha} stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem 269:26396–26401[Abstract/Free Full Text]
  37. Gardner AM, Johnson GL 1996 Fibroblast growth factor-2 suppression of tumor necrosis factor {alpha}-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J Biol Chem 271:14560–14566[Abstract/Free Full Text]
  38. Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA 1995 Ceramide activates the stress-activated protein kinases. J Biol Chem 270:22689–22692[Abstract/Free Full Text]
  39. Vietor I, Schwenger P, Li W, Schlessinger J, Vilcek J 1993 Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J Biol Chem 268:18994–18999[Abstract/Free Full Text]
  40. Winston BW, Riches DW H 1995 Activation of p42mapk/erk2 following engagement of tumor necrosis factor receptor CD120a (p55) in mouse macrophages. J Immunol 155:1525–1533[Abstract]
  41. Winston BW, Remigio LK, Riches DWH 1995 Preferential involvement of MEK1 in the tumor necrosis factor-{alpha}-induced activation of p42mapk/erk2 in mouse macrophages. J Biol Chem 270:27391–27394[Abstract/Free Full Text]
  42. Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R 1995 Phosphorylation of Raf by ceramide-activated protein kinase. Nature 378:307–310[CrossRef][Medline]
  43. Sluss HK, Barrett T, Derijard B, Davis RJ 1994 Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol 14:8376–8384[Abstract/Free Full Text]
  44. Palombella VJ, Vilcek J 1989 Mitogenic and cytotoxic actions of tumor necrosis factor in BALB/c 3T3 cells. J Biol Chem 264:18128–18136[Abstract/Free Full Text]
  45. Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM 1987 Modulation of the growth of transformed cells by human tumor necrosis factor-{alpha} and interferon-gamma. Cancer Res 47:5382–5385[Abstract/Free Full Text]
  46. Lee P-P, Hwang JJ, Ip MM 1997 Functional significance of matrix metalloproteinases (MMP) in mammary epithelial cells (MEC). Proc Annu Meet Am Assoc Cancer Res 38:406 (Abstract)
  47. Darcy KM, Wohlhueter A, Shoemaker S, Lee P-P, Varela LM, Ip MM 1997 Differential effects of epidermal growth factor receptor (EGFR) inhibition in mammary epithelial cells (MEC). Proc Annu Meet Am Assoc Cancer Res 38:56 (Abstract)
  48. Merlo GR, Graus-Porta D, Cella N, Marte BM, Taverna D, Hynes NE 1996 Growth, differentiation and survival of HC11 mammary epithelial cells: diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 70:97–105[Medline]



This article has been cited by other articles:


Home page
J Hum LactHome page
E. P. Hines, J. L. Rayner, R. Barbee, R. A. Moreland, A. Valcour, J. E. Schmid, and S. E. Fenton
Assays for Endogenous Components of Human Milk: Comparison of Fresh and Frozen Samples and Corresponding Analytes in Serum
J Hum Lact, May 1, 2007; 23(2): 144 - 156.
[Abstract] [PDF]


Home page
EndocrinologyHome page
J. Zhang, M. A. Warren, S. F. Shoemaker, and M. M. Ip
NF{kappa}B1/p50 Is Not Required for Tumor Necrosis Factor-Stimulated Growth of Primary Mammary Epithelial Cells: Implications for NF{kappa}B2/p52 and RelB
Endocrinology, January 1, 2007; 148(1): 268 - 278.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
M. D. Sternlicht, S. W. Sunnarborg, H. Kouros-Mehr, Y. Yu, D. C. Lee, and Z. Werb
Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin
Development, September 1, 2005; 132(17): 3923 - 3933.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Zhang, H. Zhang, L. Lee, and M. M. Ip
The Liver-Enriched Inhibitory Protein Isoform of CCAAT/Enhancer-Binding Protein {beta}, But Not Nuclear Factor-{kappa}B, Mediates the Transcriptional Inhibition of {beta}-Casein by Tumor Necrosis Factor-{alpha}
Endocrinology, June 1, 2004; 145(6): 2833 - 2844.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. S. Berleth, P. A. Masso-Welch, L. A. Kazim, M. M. Ip, E. Mihich, and M. J. Ehrke
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein
J. Leukoc. Biol., June 1, 2001; 69(6): 995 - 1005.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. K. Shea-Eaton, P.-P. H. Lee, and M. M. Ip
Regulation of Milk Protein Gene Expression in Normal Mammary Epithelial Cells by Tumor Necrosis Factor
Endocrinology, June 1, 2001; 142(6): 2558 - 2568.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P.-P. H. Lee, J.-J. Hwang, G. Murphy, and M. M. Ip
Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells
Endocrinology, October 1, 2000; 141(10): 3764 - 3773.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
K. M. Darcy, D. Zangani, A. L. Wohlhueter, R.-Y. Huang, M. M. Vaughan, J. A. Russell, and M. M. Ip
Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during Growth, Differentiation, and Apoptosis of Normal Rat Mammary Epithelial Cells
J. Histochem. Cytochem., January 1, 2000; 48(1): 63 - 80.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varela, L. M.
Right arrow Articles by Ip, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varela, L. M.
Right arrow Articles by Ip, M. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals